📈#BigPharma continues to set out-of-control prices, especially on newly launched brand name products. Get a dose of reality on Big Pharma’s egregious prices for their highest priced products:.

A new report from @FiercePharma details the most expensive #RxDrugs in the U.S. in 2025 – providing an opportunity to analyze the gap between #BigPharma’s out-of-control prices and clinical value for patients. See how #BigPharma’s prices far exceed @ICER’s fair price estimates:.

ICYMI: #BigPharma giants Gilead and Eli Lilly reported second quarter earnings that beat Wall Street analysts’ estimates after the pair started 2025 with price hikes on more than 10 of their brand name products each. Get the full recap:.

The @FTC/@TheJusticeDept joint session this week highlighted bipartisan, market-based solutions to improve competition to lower drug prices in America, including the bipartisan work of the @SenJudiciaryGOP to hold #BigPharma accountable under @ChuckGrassley’s leadership. More ⬇️.

THEY SAID IT: In Monday’s joint @FTC/@TheJusticeDept listening session, @JohnCornyn’s chief counsel highlighted The Affordable Prescriptions for Patients Act, which would crack down on #BigPharma’s egregious patent thickets that extend monopolies and keep #RxPrices high. More:.

ICYMI: Amgen and Pfizer were the latest brand name drug companies to continue the #BigPharma streak – beating Wall Street expectations for second quarter earnings after continuing to hike prices on their blockbuster products. Get the full recap:.

ICYMI: The @FTC and @TheJusticeDept held a listening session on Monday with policy and legal experts representing the offices of U.S. Senators @JohnCornyn, @SenMikeLee and @ChuckGrassley to discuss lowering #RxDrug prices in the U.S. by fostering greater competition. Learn more:.

DOSE OF REALITY: A @WSJ report finds a recently passed #BigPharma-supported policy is likely to cost seniors and taxpayers far more in higher prescription drug prices than previously estimated. Congress should protect seniors and taxpayers by repealing the policy. Learn more:.

#BigPharma giants AbbVie and Bristol Myers Squibb reported Q2 earnings that exceeded Wall Street analysts’ expectations after hiking prices on blockbuster products earlier this year. Get the full recap:.

Big Pharma’s staggering spending on DTC advertising (nearly $14 billion in 2023 alone) increases spending on high-priced brand name blockbusters, as well as patient uptake of medications with low clinical value, or that they may not need. Get the facts:.

#BigPharma giant @JNJNews continues to post profits that soar past Wall Street analysts’ revenue expectations, driven by repeated price hikes and anti-competitive practices. More here ⬇️.

BIG PHARMA EARNINGS WATCH: AstraZeneca & GSK once again beat Wall Street analysts’ Q2 forecasts after hiking prices on nearly 50 blockbuster drugs combined this year. Full recap here:

In Thursday's hearing on health care affordability, CSRxP encourages the HELP Committee to highlight Big Pharma's egregious pricing and anti-competitive practices that are the root cause of out-of-control drug prices. More on bipartisan solutions to hold Big Pharma accountable:.

Second Opinion: A recent @PostOpinions editorial draws the wrong conclusion on the clinical value of #BigPharma’s DTC advertising – dismissing the proven connection between BILLIONS in ad spending and higher #RxDrug prices. Learn more ⬇️.

BIG PHARMA EARNINGS WATCH: Roche, like many of its #BigPharma peers, consistently beats Wall Street analysts’ revenue expectations while continuing to engage in anti-competitive practices & hike prices on blockbuster drugs in its portfolio. Get the recap on Roche’s earnings:.

We commend @ChuckGrassley and @SenatorDurbin's commitment to shining a light on Big Pharma’s egregious pricing practices with greater list price transparency in brand name drug companies’ advertising targeting consumers – and encourage the Senate to pass their bipartisan DTC Act.

👏#BigPharma's staggering spending on advertising directly targeting consumers increases spending on high priced brand-name drugs. @SenatorDurbin & @ChuckGrassley's bill would help shine a light on Big Pharma's egregious prices and arm the public with information.

BIG PHARMA WATCH: #BigPharma giant Johnson & Johnson reported earnings that beat Wall Street analysts’ Q2 expectations after hiking #RxDrug prices 30 times this year. Full recap here:.

Brand name drug companies focus on their most profitable products for reformulation to file more patents, extend monopolies and undermine competition from more affordable alternatives. Learn more about #BigPharma’s patent abuse:.

The pharmaceutical industry’s egregious abuse of the patent system is a root cause of high #RxDrug prices, enabling #BigPharma to repeatedly hike prices on existing drugs and block patients from accessing more affordable alternatives. Learn more:.